← Back to Screener
MeiraGTx Holdings plc Ordinary Shares (MGTX)
Price$10.53
Favorite Metrics
Price vs S&P 500 (26W)20.33%
Price vs S&P 500 (4W)31.06%
Market Capitalization$857.63M
All Metrics
Book Value / Share (Quarterly)$0.04
P/TBV (Annual)7.10x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)72.27%
Cash Flow / Share (Quarterly)$-0.62
Price vs S&P 500 (YTD)23.16%
Gross Margin (TTM)94.05%
Net Profit Margin (TTM)-140.31%
EPS (TTM)$-1.43
10-Day Avg Trading Volume1.26M
EPS Excl Extra (TTM)$-1.43
Revenue Growth (5Y)39.22%
EPS (Annual)$-1.42
ROI (Annual)-104.78%
Gross Margin (Annual)94.05%
Net Profit Margin (5Y Avg)-441.82%
Cash / Share (Quarterly)$0.81
Revenue Growth QoQ (YoY)252.33%
ROA (Last FY)-46.72%
Revenue Growth TTM (YoY)144.57%
EBITD / Share (TTM)$-1.16
ROE (5Y Avg)-91.21%
Operating Margin (TTM)-130.20%
Cash Flow / Share (Annual)$-0.62
P/B Ratio289.74x
P/B Ratio (Quarterly)177.20x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)10.64x
Net Interest Coverage (TTM)-13.13x
ROA (TTM)-53.33%
EPS Incl Extra (Annual)$-1.42
Current Ratio (Annual)0.75x
Quick Ratio (Quarterly)0.70x
3-Month Avg Trading Volume0.56M
52-Week Price Return90.23%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.03
P/S Ratio (Annual)10.54x
Asset Turnover (Annual)0.33x
52-Week High$11.85
Operating Margin (5Y Avg)-505.07%
EPS Excl Extra (Annual)$-1.42
CapEx CAGR (5Y)-30.17%
Tangible BV CAGR (5Y)-18.82%
26-Week Price Return29.08%
Quick Ratio (Annual)0.70x
13-Week Price Return35.84%
Total Debt / Equity (Annual)1.08x
Current Ratio (Quarterly)0.75x
Enterprise Value$866.181
Revenue / Share Growth (5Y)19.66%
Asset Turnover (TTM)0.38x
Book Value / Share Growth (5Y)-30.10%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-140.31%
Cash / Share (Annual)$0.81
3-Month Return Std Dev69.74%
Net Income / Employee (TTM)$-0
ROE (Last FY)-217.89%
Net Interest Coverage (Annual)-1.24x
EPS Basic Excl Extra (Annual)$-1.42
Receivables Turnover (TTM)34.95x
Total Debt / Equity (Quarterly)24.92x
EPS Incl Extra (TTM)$-1.43
Receivables Turnover (Annual)34.95x
ROI (TTM)-127.78%
P/S Ratio (TTM)10.54x
Pretax Margin (5Y Avg)-441.82%
Revenue / Share (Annual)$1.01
Tangible BV / Share (Annual)$0.85
Price vs S&P 500 (52W)55.13%
Year-to-Date Return27.30%
5-Day Price Return5.09%
EPS Normalized (Annual)$-1.42
ROA (5Y Avg)-38.56%
Net Profit Margin (Annual)-140.31%
Month-to-Date Return16.86%
Cash Flow / Share (TTM)$-2.29
EBITD / Share (Annual)$-1.32
Operating Margin (Annual)-130.20%
LT Debt / Equity (Annual)1.08x
ROI (5Y Avg)-56.13%
LT Debt / Equity (Quarterly)24.92x
EPS Basic Excl Extra (TTM)$-1.43
P/TBV (Quarterly)236.48x
P/B Ratio (Annual)7.02x
Inventory Turnover (TTM)25.16x
Pretax Margin (TTM)-140.31%
Book Value / Share (Annual)$0.87
Price vs S&P 500 (13W)32.97%
Beta1.33x
P/FCF (Annual)77.54x
Revenue / Share (TTM)$1.00
ROE (TTM)-315.61%
52-Week Low$4.55
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MGTXMeiraGTx Holdings plc Ordinary Shares | 10.54x | 144.57% | 94.05% | — | $10.53 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
MeiraGTx Holdings is a clinical-stage gene therapy company developing AAV-based treatments for genetic disorders affecting the eye, salivary gland, and central nervous system. Its pipeline includes programs such as AAV-CNGB3 and AAV-RPGR targeting inherited retinal dystrophies and other rare genetic conditions. The company operates across the United States, United Kingdom, and European Union.